Cross-protection of the Bivalent Human Papillomavirus (HPV) Vaccine Against Variants of Genetically Related High-Risk HPV Infections

Costa Rica HPV Vaccine Trial Group

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background. Results from the Costa Rica Vaccine Trial (CVT) demonstrated partial cross-protection by the bivalent human papillomavirus (HPV) vaccine, which targets HPV-16 and HPV-18, against HPV-31, -33, and -45 infection and an increased incidence of HPV-51 infection. Methods. A study nested within the CVT intention-to-treat cohort was designed to assess high-risk HPV variant lineage-specific vaccine efficacy (VE). The 2 main end points were (1) long-term incident infections persisting for ≥2 years and/or progression to high-grade squamous intraepithelial lesions (ie, cervical intraepithelial neoplasia grade 2/3 [CIN 2/3]) and (2) incident transient infections lasting for

Original languageEnglish (US)
Pages (from-to)939-947
Number of pages9
JournalJournal of Infectious Diseases
Volume213
Issue number6
DOIs
StatePublished - Mar 15 2016

Fingerprint

Cross Protection
Papillomavirus Vaccines
Papillomavirus Infections
Costa Rica
Vaccines
Human papillomavirus 31
Infection
Human papillomavirus 18
Cervical Intraepithelial Neoplasia
Human papillomavirus 16
Incidence

Keywords

  • cross-protection
  • HPV vaccine
  • HPV variants

ASJC Scopus subject areas

  • Infectious Diseases
  • Immunology and Allergy

Cite this

Cross-protection of the Bivalent Human Papillomavirus (HPV) Vaccine Against Variants of Genetically Related High-Risk HPV Infections. / Costa Rica HPV Vaccine Trial Group.

In: Journal of Infectious Diseases, Vol. 213, No. 6, 15.03.2016, p. 939-947.

Research output: Contribution to journalArticle

@article{d815d6d17bff4428bb60e3071aa10014,
title = "Cross-protection of the Bivalent Human Papillomavirus (HPV) Vaccine Against Variants of Genetically Related High-Risk HPV Infections",
abstract = "Background. Results from the Costa Rica Vaccine Trial (CVT) demonstrated partial cross-protection by the bivalent human papillomavirus (HPV) vaccine, which targets HPV-16 and HPV-18, against HPV-31, -33, and -45 infection and an increased incidence of HPV-51 infection. Methods. A study nested within the CVT intention-to-treat cohort was designed to assess high-risk HPV variant lineage-specific vaccine efficacy (VE). The 2 main end points were (1) long-term incident infections persisting for ≥2 years and/or progression to high-grade squamous intraepithelial lesions (ie, cervical intraepithelial neoplasia grade 2/3 [CIN 2/3]) and (2) incident transient infections lasting for",
keywords = "cross-protection, HPV vaccine, HPV variants",
author = "{Costa Rica HPV Vaccine Trial Group} and Ariana Harari and Zigui Chen and Rodr{\'i}guez, {Ana Cecilia} and Allan Hildesheim and Carolina Porras and Rolando Herrero and Sholom Wacholder and Panagiotou, {Orestis A.} and Brian Befano and Burk, {Robert D.} and Mark Schiffman",
year = "2016",
month = "3",
day = "15",
doi = "10.1093/infdis/jiv519",
language = "English (US)",
volume = "213",
pages = "939--947",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - Cross-protection of the Bivalent Human Papillomavirus (HPV) Vaccine Against Variants of Genetically Related High-Risk HPV Infections

AU - Costa Rica HPV Vaccine Trial Group

AU - Harari, Ariana

AU - Chen, Zigui

AU - Rodríguez, Ana Cecilia

AU - Hildesheim, Allan

AU - Porras, Carolina

AU - Herrero, Rolando

AU - Wacholder, Sholom

AU - Panagiotou, Orestis A.

AU - Befano, Brian

AU - Burk, Robert D.

AU - Schiffman, Mark

PY - 2016/3/15

Y1 - 2016/3/15

N2 - Background. Results from the Costa Rica Vaccine Trial (CVT) demonstrated partial cross-protection by the bivalent human papillomavirus (HPV) vaccine, which targets HPV-16 and HPV-18, against HPV-31, -33, and -45 infection and an increased incidence of HPV-51 infection. Methods. A study nested within the CVT intention-to-treat cohort was designed to assess high-risk HPV variant lineage-specific vaccine efficacy (VE). The 2 main end points were (1) long-term incident infections persisting for ≥2 years and/or progression to high-grade squamous intraepithelial lesions (ie, cervical intraepithelial neoplasia grade 2/3 [CIN 2/3]) and (2) incident transient infections lasting for

AB - Background. Results from the Costa Rica Vaccine Trial (CVT) demonstrated partial cross-protection by the bivalent human papillomavirus (HPV) vaccine, which targets HPV-16 and HPV-18, against HPV-31, -33, and -45 infection and an increased incidence of HPV-51 infection. Methods. A study nested within the CVT intention-to-treat cohort was designed to assess high-risk HPV variant lineage-specific vaccine efficacy (VE). The 2 main end points were (1) long-term incident infections persisting for ≥2 years and/or progression to high-grade squamous intraepithelial lesions (ie, cervical intraepithelial neoplasia grade 2/3 [CIN 2/3]) and (2) incident transient infections lasting for

KW - cross-protection

KW - HPV vaccine

KW - HPV variants

UR - http://www.scopus.com/inward/record.url?scp=84964854218&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964854218&partnerID=8YFLogxK

U2 - 10.1093/infdis/jiv519

DO - 10.1093/infdis/jiv519

M3 - Article

C2 - 26518044

AN - SCOPUS:84964854218

VL - 213

SP - 939

EP - 947

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 6

ER -